Generics Demand Stronger Proscriptions in REMS Compliance Letter Guidance

FDAnews Drug Daily Bulletin
Pharmaceuticals / Postmarket Safety / Submissions and Approvals
Generics Demand Stronger Proscriptions in REMS Compliance Letter Guidance

Generic drugmakers charge a December draft guidance doesn’t go far enough in enabling them to obtain bioequivalence testing batches for drugs protected by REMS product safety protocols.

> Read more here

Related News

lab vial icon

New Product Development

Where our FDA approved laboratory begins developing products, formulating and validating methods to ensure quality.

arrow icon
magnifier icon

Compliance Audits

Where we audit and champion our partner factories to exceed cGMP standards set by authorities.

arrow icon
forms icon

Regulatory Services

Where all submissions are filed with the knowledge and experience of our 550+ worldwide approvals on record.

arrow icon